Rahul Aggarwal

MD

Developmental therapeutics specialist
Genitourinary oncologist
Cancer researcher and sports enthusiast

About me

Dr. Rahul Aggarwal is a specialist in cancers of the genital and urinary organs. He cares for patients at the UCSF Helen Diller Family Comprehensive Cancer Center. He also serves as director of the UCSF STAND (Supportive Therapy in Androgen Deprivation) Clinic, which provides comprehensive care to men who are receiving androgen deprivation therapy, hormone therapy for prostate cancer.

As a member of the Developmental Therapeutics Genitourinary Cancer Program, Aggarwal enrolls patients with advanced solid tumor malignancies into early-phase clinical trials of novel targeted treatments. His research focuses on developing hormonal treatment strategies that reduce the toxicity of androgen deprivation therapy for men with advanced prostate cancer. He is also interested in developing new molecular imaging techniques that will help predict how advanced solid tumors will respond to treatment.

Aggarwal earned his medical degree from the Northwestern University Feinberg School of Medicine. At UCSF, he completed an internship and residency in internal medicine, followed by a clinical fellowship in hematology and oncology.

Aggarwal has also been a research fellow in developmental therapeutics at Genentech. He is a member of the American Society of Clinical Oncology (ASCO) and recipient of the ASCO/Conquer Cancer Foundation Young Investigator Award.

  • Education

    Northwestern University Feinberg School of Medicine, 2006

  • Residencies

    UCSF Medical Center, Internal Medicine, 2009

  • Fellowships

    UCSF Medical Center, Hematology/Oncology, 2013

  • Academic Title

    Associate Professor

It's an honor to help take care of people with cancer, and I strive each and every day to improve outcomes for our patients.

Conditions I specialize in

Center for Neuroendocrine Tumors

Bakar Precision Cancer Medicine Building

1825 Fourth St.
San Francisco, CA 94158

(415) 476-2212
M-F, 8:30 a.m. - 5 p.m.

Genitourinary Medical Oncology Clinic

Bakar Precision Cancer Medicine Building

1825 Fourth St., Sixth Floor
San Francisco, CA 94158

(415) 476-4616
M-F, 8 a.m. - 5 p.m.

STAND Clinic

Bakar Precision Cancer Medicine Building

1825 Fourth St., Sixth Floor
San Francisco, CA 94158

(415) 885-7795

My reviews

5.0

Overall Experience
305 Reviews
Dr. Aggarwal is an exceptional health care provider. He listens attentively to everything I say and addresses all my needs and concerns. He is without doubt the best doctor I have had the privilege of treating me.
Explained things in a way that was easy to understand
303 Reviews
Did the doctor pay attention to your concerns
305 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
303 Reviews
Knew the important information about your medical history
303 Reviews
The provider showed respect for what you had to say
303 Reviews
The provider spent enough time with me
303 Reviews
Read all reviews About our process

Selected research

Decorative Caduceus

PROMOTE: Identifying Predictive Markers of Response for Prostate Cancer

RECIST v.1.1

Recruiting

Decorative Caduceus

Apalutamide With or Without Stereotactic Body Radiation Therapy in Treating Participants With C...

The primary endpoint for the study is the proportion of patients with undetectable serum PSA (< 0.2 ng/mL) at 6 months following completion of apalutamide therapy (18 months from date of randomization). Fisher's exact test will be...

Recruiting

Decorative Caduceus

COMbination of Bipolar Androgen Therapy and Nivolumab

Number of participants with PSA response to Bipolar Androgen Therapy + Nivolumab. PSA response is counted for participants with ≥ 50% decline in PSA from baseline.

Recruiting

Decorative Caduceus

Phase II Trial of AZD6738 Alone and in Combination With Olaparib

Will be based on one-sided exact binomial test comparison of the observed ORR in evaluable patients to the null-hypothesized value of 5%, using the 5% significance level.

Recruiting

Decorative Caduceus

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

Progression free survival

Recruiting

Decorative Caduceus

Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (HP) (13C) in Castration-Resistant...

ASI-refractory disease is defined as progression by PCWG2 criteria within 6 months of treatment initiation. ASI-responsive disease includes all other tumors not meeting this criterion.

Recruiting

Decorative Caduceus

A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Comb...

DLT as graded using National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI-CTCAE] Version 4.03. The DLT observation period may be increased if deemed appropriate by the Dose Escalation and Safety Committee

Recruiting

Decorative Caduceus

A Phase 1b Dose Escalation/Expansion Study of Abexinostat in Combination With Pembrolizumab in ...

Recruiting

Decorative Caduceus

Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies

Recruiting

Decorative Caduceus

Gallium-68 Citrate PET Used in Prostate Cancer

Mean maximum Standardized Uptake Value (SUV) across all metastatic lesions per patient.

Recruiting

Contact me

Providers on my team

Share